merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer option than compounded drugs for people who cannot afford its pens.</answer>
<question_number>2</question_number>
<answer>LillyDirect connects patients with providers who can prescribe obesity drugs, offering a direct-to-consumer model that competes with telehealth companies by providing a safer, company-backed alternative.</answer>
<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than traditionally approved medications, posing safety, quality, and effectiveness concerns.</answer>
<question_number>4</question_number>
<answer>It is seen as a strategic move because it could attract customers currently using compounded versions of tirzepatide back to Eli Lilly's officially approved product, despite the lower price potentially reducing profits from its higher-priced pens.</answer>
<question_number>5</question_number>
<answer>The FDA's shortage list allows compounding pharmacies to make copycat versions of medications listed as "in shortage," including tirzepatide, which Eli Lilly aims to challenge legally.</answer>
<question_number>6</question_number>
<answer>Eli Lilly's pricing strategy reflects a trend towards transparent pricing and direct-to-consumer sales by removing third-party supply chain entities.</answer>
<question_number>7</question_number>
<answer>N/A</answer>
<question_number>8</question_number>
<answer>By offering a safer, FDA-approved alternative directly to consumers, Eli Lilly's introduction of Zepbound vials could improve safety perceptions among patients wary of the risks associated with compounded drugs.</answer>
<question_number>9</question_number>
<answer>Tirzepatide is listed by the FDA as "in shortage," which allows compounding pharmacies to produce alternative versions.</answer>
<question_number>10</question_number>
<answer>Lower pricing.</answer>